Detailed characteristics of CEBPA-silenced AML samples showed that they expressed both, myeloid markers (CD13, CD33, and MPO), and T-lymphoid markers (e.g., CD7 mentioned above). This evidence concerns the gene CD7 and acute myeloid leukemia.